Enlivex Therapeutics Ltd. - Class A common stock (ENLV) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2019 to Q4 2025

Type / Class
Equity / Class A common stock
Symbol
ENLV on Nasdaq
Shares outstanding
4,195,190
Price per share
$0.70
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
904,520
Total reported value
$940,163
% of total 13F portfolios
0%
Share change
-1,647,973
Value change
-$1,876,489
Number of holders
28
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Enlivex Therapeutics Ltd. - Class A common stock (ENLV) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ARMISTICE CAPITAL, LLC 5% $228,181 209,340 Armistice Capital, LLC 30 Jun 2025

As of 30 Sep 2025, 28 institutional investors reported holding 904,520 shares of Enlivex Therapeutics Ltd. - Class A common stock (ENLV). This represents 22% of the company’s total 4,195,190 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Enlivex Therapeutics Ltd. - Class A common stock (ENLV) together control 22% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
CITIZENS FINANCIAL GROUP INC/RI 5.5% 231,424 0% $240,681
MORGAN STANLEY 4.1% 173,625 -21% 0% $180,570
RENAISSANCE TECHNOLOGIES LLC 3.7% 157,292 -6.6% 0% $163,584
CITADEL ADVISORS LLC 1.6% 68,936 0% $71,693
SUSQUEHANNA INTERNATIONAL GROUP, LLP 1.3% 54,850 0% $57,044
XTX Topco Ltd 1% 42,668 0% $44,375
TWO SIGMA SECURITIES, LLC 0.82% 34,242 0.01% $35,612
SIGMA INVESTMENT COUNSELORS INC 0.67% 28,000 0% 0% $29,120
JANE STREET GROUP, LLC 0.51% 21,529 -65% 0% $22,390
HRT FINANCIAL LP 0.45% 18,792 0% $19,000
Prosperity Consulting Group, LLC 0.42% 17,647 0% $18,353
NEUBERGER BERMAN GROUP LLC 0.26% 10,988 0% 0% $11,428
TWO SIGMA INVESTMENTS, LP 0.26% 10,739 0% $11,169
WELLS FARGO & COMPANY/MN 0.22% 9,184 0% 0% $9,551
GROUP ONE TRADING LLC 0.17% 7,000 0% 0% $7,280
SIGNATUREFD, LLC 0.12% 5,000 0% 0% $5,200
UBS Group AG 0.1% 4,040 0% $4,202
Steward Partners Investment Advisory, LLC 0.06% 2,500 0% 0% $2,600
OSAIC HOLDINGS, INC. 0.05% 2,130 -70% 0% $2,219
Arax Advisory Partners 0.02% 1,015 0% 0% $1,056
BFSG, LLC 0.02% 1,000 0% 0% $1,040
Activest Wealth Management 0.02% 1,000 0% 0% $1,040
Spire Wealth Management 0.01% 500 0% 0% $520
Red Tortoise LLC 0% 150 0% 0% $156
BANK OF AMERICA CORP /DE/ 0% 125 -96% 0% $130

Institutional Holders of Enlivex Therapeutics Ltd. - Class A common stock (ENLV) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 1,150 $809 -$5,720 $0.70 2
2025 Q3 904,520 $940,163 -$1,876,489 $1.04 28
2025 Q2 2,562,493 $2,870,793 -$660,551 $1.12 21
2025 Q1 3,172,878 $3,077,787 -$231,380 $0.97 26
2024 Q4 3,410,244 $3,988,505 +$965,901 $1.17 24
2024 Q3 2,564,823 $4,308,904 +$807,487 $1.68 20
2024 Q2 2,084,177 $2,959,532 +$2,158,086 $1.42 17
2024 Q1 326,146 $1,236,215 +$436,469 $3.79 15
2023 Q4 188,457 $509,494 -$102,359 $2.70 17
2023 Q3 256,634 $406,818 -$97,129 $1.58 15
2023 Q2 302,487 $795,439 -$107,223 $2.63 20
2023 Q1 343,260 $1,238,359 +$17,014 $3.64 19
2022 Q4 337,460 $1,313,998 +$74,409 $3.92 21
2022 Q3 333,639 $1,414,000 -$1,408,180 $4.25 20
2022 Q2 604,532 $2,890,000 -$1,186,954 $4.52 21
2022 Q1 831,798 $4,651,000 +$923,493 $5.60 22
2021 Q4 662,157 $4,112,000 -$1,211,991 $6.24 19
2021 Q3 847,653 $8,382,460 -$1,349,427 $9.88 19
2021 Q2 987,814 $8,789,216 -$1,492,870 $8.90 21
2021 Q1 1,059,657 $11,730,140 +$7,345,091 $11.08 24
2020 Q4 398,346 $3,358,000 +$295,127 $8.43 11
2020 Q3 321,043 $1,906,000 -$156,743 $5.93 4
2020 Q2 355,221 $1,797,000 -$3,024,296 $5.05 7
2020 Q1 959,592 $4,493,000 +$3,963,186 $4.69 6
2019 Q4 80,217 $672,000 -$189,113 $8.37 4
2019 Q3 50,751 $1,355,000 +$782,948 $26.70 4
2019 Q2 21,430 $461,000 +$80,362 $21.47 2
2019 Q1 17,689 $219,000 +$219,000 $12.38 1